ArticleDrug discovery today. Therapeutic strategies2013
Visual Function Endpoints to Enable Dry AMD Clinical Trials.
Article in Drug discovery today. Therapeutic strategies, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Design characteristic of randomised controlled trials for geographic atrophy in age-related macular degeneration: selection of outcomes and sample size calculation.Eye (London, England) · 2015Pooled it
- [From phase I-IV-Correctly understand and assess study designs in ophthalmology].Die Ophthalmologie · 2026Article
- Geographic Atrophy Size Progression Correlates Better with Longitudinal Changes in Quantitative Contrast Sensitivity than Visual Acuity.Ophthalmology science · 2026Article
- Using the Rate of Global and Pointwise Microperimetry Change to Predict Structural Conversion in Intermediate Age-Related Macular Degeneration.Ophthalmology science · 2026Article
- Importance of Screening for Contrast Sensitivity, Falls, and Mobility Limitations in Older Adults With Maculopathy.American journal of ophthalmology · 2025Article
- Ellipsoid zone reflectivity as a functional imaging biomarker for age-related macular degeneration: a MACUSTAR study report.Scientific reports · 2025Article
- Expert CONsensus on Visual Evaluation in Retinal disease manaGEment: the CONVERGE study.The British journal of ophthalmology · 2025Article
- Using Hierarchical Bayesian Modeling to Enhance Statistical Inference on Contrast Sensitivity.Translational vision science & technology · 2024Article
- Effectiveness of Mp-3 Microperimetric Biofeedback Fixation Training For Low Vision Rehabilitation in Patients Treated With Corticosteroid Ivt in Retinal Vein Occlusions.Clinical optometry · 2024Article
- Dark Adaptation and Its Role in Age-Related Macular Degeneration.Journal of clinical medicine · 2022Review
- Progress of clinical therapies for dry age-related macular degeneration.International journal of ophthalmology · 2022Review
- Contrast Sensitivity Is Associated With Chorioretinal Thickness and Vascular Density of Eyes in Simple Early-Stage High Myopia.Frontiers in medicine · 2022Article
- Hierarchical Bayesian modeling of contrast sensitivity functions in a within-subject design.Journal of vision · 2021Article
- Active Learning of Contrast Sensitivity to Assess Visual Function in Macula-off Retinal Detachment.Journal of vitreoretinal diseases · 2021Article
- Measuring the Contrast Sensitivity Function in Non-Neovascular and Neovascular Age-Related Macular Degeneration: The Quantitative Contrast Sensitivity Function Test.Journal of clinical medicine · 2021Review
- Clinical Perspectives and Trends: Microperimetry as a Trial Endpoint in Retinal Disease.Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde · 2021Review
- Portable Diagnostic System for Age-Related Macular Degeneration Screening Using Visual Evoked Potentials.Eye and brain · 2021Article
- Longitudinal Study of Visual Function in Dry Age-Related Macular Degeneration at 12 Months.Ophthalmology. Retina · 2019Article
- Measuring the Contrast Sensitivity Function Using the qCSF Method With 10 Digits.Translational vision science & technology · 2018Article
- VISUAL FUNCTION MEASURES IN EARLY AND INTERMEDIATE AGE-RELATED MACULAR DEGENERATION.Retina (Philadelphia, Pa.) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The slow progression of non-exudative age-related macular degeneration (dry AMD) presents challenges for drug discovery. The standard endpoint used for ophthalmic clinical trials, best-corrected visual acuity, is insensitive to the early stages and slow progression of dry AMD. Effective drug discovery for dry AMD treatments will therefore require novel applications of more effective visual function endpoints. This review will present candidates for visual function endpoints for dry AMD clinical trials. The promising visual assessments include contrast sensitivity, reading speed, microperimetry, and dark adaptation. Their adoption as exploratory endpoints in future trials will be critical for determining their accuracy, precision, and applicability, and ultimately determine their value for drug discovery.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.